The pharmaceutical market in Indonesia more than doubled from just under $3 billion in 2008 to reach approximately $7 billion in 2015 and is anticipated to increase further to $12.6 billion by 2020, driven primarily by the Indonesian government’s economic and healthcare initiatives. Indonesia’s pharmaceutical sector will be boosted by the establishment of a universal healthcare scheme, known as the Jaminan Kesehatan Nasional. This was launched in January 2014 with the aim of providing health insurance to 250 million Indonesian citizens by 2019, which would make it the world’s largest social health insurance. New economic policy packages, the high prevalence of infectious diseases, widespread generic drug supply, increasing affordability of healthcare products and the large over-the-counter medicines market will also help to drive growth in Indonesia’s pharmaceutical sector.
GlobalData’s “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Indonesia” report provides information on Indonesia’s healthcare, regulatory, and reimbursement landscape, with annualized market data on the pharmaceutical and medical devices sectors from 2014 and forecast to 2020. It includes detailed analysis of the political and economic environment, covering economic indicators, demographics, and healthcare infrastructure and expenditure in Indonesia.
Published: Feb’16 – Single user price: $1,995